Acrivon Therapeutics, Inc. (ACRV)
(Delayed Data from NSDQ)
$9.36 USD
+0.67 (7.71%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $9.25 -0.11 (-1.18%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Price, Consensus and EPS Surprise
ACRV 9.36 +0.67(7.71%)
Will ACRV be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ACRV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ACRV
Are Medical Stocks Lagging Acrivon Therapeutics, Inc. (ACRV) This Year?
Verastem (VSTM) Begins Dosing in Solid Tumors Study in China
ACRV: What are Zacks experts saying now?
Zacks Private Portfolio Services
AbbVie (ABBV) Files for Rinvoq in Giant Cell Arteritis in US & EU
SpringWorks (SWTX) Rises More Than 40% in a Year: Here's Why
Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up
Other News for ACRV
Acrivon Therapeutics: A Buy Rating Justified by Clinical Advances and Financial Stability
Acrivon Therapeutics, Inc.: A Promising Buy Amidst Clinical Advancements and Robust Pipeline Developments
Acrivon Therapeutics, Inc.: A Strong Buy on Robust Clinical Prospects and Financial Stability
ACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q2 2024
Promising Acrivon Trial Results and Market Opportunity Support Buy Rating